What the FDA labels say about taking them together
Ivabradine and voriconazole
Voriconazole's FDA label of February 26, 2026 names ivabradine in its drug interactions section; ivabradine's label does not name voriconazole itself but warns about its class (Azole antifungals). The voriconazole label: “Contraindicated because of potential for QT prolongation and rare occurrence of torsade de pointes.”
Check it at the source: the ivabradine FDA label on DailyMed (effective November 10, 2025); the voriconazole FDA label on DailyMed (effective February 26, 2026, Roerig).
What does the ivabradine label say about voriconazole?
Ivabradine's label does not name voriconazole itself; it warns about its class (Azole antifungals):
Ivabradine label, drug interactionsThe concomitant use of strong CYP3A4 inhibitors is contraindicated [ s ee Contraindications ( 4 ) and Clinical Pharmacology ( 12.3 )]. Examples of strong CYP3A4 inhibitors include azole antifungals (e.g., itraconazole), macrolide antibiotics (e.g., clarithromycin, telithromycin), HIV protease inhibitors (e.g., nelfinavir), and nefazodone.
Source: FDA drug label (Corlanor), Amgen Inc, effective November 10, 2025 (SPL set 92018a65-38f6-45f7-91d4-a34921b81d0d), via openFDA; the full label on DailyMed
What does the voriconazole label say about ivabradine?
Voriconazole label, drug interactionsDrug/Drug Class (Mechanism of Interaction by Voriconazole): Pimozide, Quinidine, Ivabradine (CYP3A4 Inhibition); Drug Plasma Exposure (C max and AUC τ): Not Studied In Vivo or In Vitro, but Drug Plasma Exposure Likely to be Increased; Prevention or Management Recommendations: Contraindicated because of potential for QT prolongation and rare occurrence of torsade de pointes.
Voriconazole label (Xellia Pharmaceuticals USA LLC, January 11, 2023), contraindicationsCoadministration of pimozide, quinidine or ivabradine with Voriconazole for injection is contraindicated because increased plasma concentrations of these drugs can lead to QT prolongation and rare occurrences of torsade de pointes [see Drug Interactions (7) ].
Voriconazole label (Xellia Pharmaceuticals USA LLC, January 11, 2023), drug interactionsDrug/Drug Class (Mechanism of Interaction by Voriconazole): Pimozide, Quinidine, Ivabradine (CYP3A4 Inhibition); Drug Plasma Exposure (C max and AUC τ): Not Studied In Vivo or In Vitro, but Drug Plasma Exposure Likely to be Increased; Recommendations for Drug Dosage Adjustment/Comments: Contraindicated because of potential for QT prolongation and rare occurrence of torsade de pointes
Source: FDA drug label (Voriconazole, NDA208562), Xellia Pharmaceuticals USA LLC, effective January 11, 2023 (SPL set 9ec6eda2-2f15-423b-9ec6-819379a426e1), via openFDA
Source: FDA drug label (VFEND), NDA021630 (Pf Prism Cv), as published by Roerig, effective February 26, 2026 (SPL set ce3ef5cf-3087-4d92-9d94-9eb8287228db), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Ivabradine | Voriconazole | |
|---|---|---|
| Labeled for | Heart failure | Fungal infections |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.761 per tablet 5 mg tablet | $1.88 per tablet 200 mg tablet |
| Shortage now | A presentation being discontinued | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once